CBN and Sleep: Simply Explained
Published: Journal of Sleep Research, February 2026
Researchers: Isobel Lavender, Ron Grunstein, Camilla Hoyos et al. — Woolcock Institute of Medical Research, Sydney, Australia — the CUPID Trial
1. What Was Studied?
CBN (cannabinol) is quietly becoming one of the most marketed cannabinoids for sleep. It appears in gummies, tinctures, and capsules sold specifically as sleep aids — often with bold claims about its sedative properties.
This study — the first randomized placebo-controlled clinical trial of CBN specifically in adults with diagnosed insomnia — tested whether those claims hold up under controlled conditions. Twenty adults with clinically diagnosed insomnia disorder spent three separate nights in a sleep lab, each receiving either 30mg CBN, 300mg CBN, or a placebo, in random order. Sleep was measured objectively overnight using polysomnography — full brain and body monitoring.
2. What Did They Find?
Neither dose of CBN significantly reduced wake time after sleep onset — the trial's primary measure — meaning the main claim made about CBN for sleep was not confirmed
The 300mg dose did halve average sleep onset time, from 14 minutes to seven — a meaningful improvement similar to effects seen with melatonin
300mg CBN increased time spent in stage 2 non-REM sleep (the transitional stage between light and deep sleep)
Subjective sleep quality improved at the 300mg dose
CBN also reduced nighttime arousal counts at 300mg
The 30mg dose — far closer to what is found in most consumer products — showed little meaningful effect
No serious adverse events were reported
3. What This Means
This is an important and nuanced result. CBN didn't pass its primary test — it didn't reduce how long people stayed awake after first falling asleep, which is the most clinically meaningful measure for insomnia. But it did show some real secondary benefits at a very high dose, particularly around falling asleep faster.
The dose finding is critical for consumers. Most CBN sleep products on the market contain 5mg to 25mg — a tiny fraction of the 300mg that showed any meaningful effect here. This study suggests the claims made about low-dose CBN for sleep are significantly ahead of the evidence.
4. What This Does NOT Mean
This does not mean CBN has no effect on sleep — the secondary findings at 300mg are genuinely interesting
This was a single-night trial with 20 participants — it cannot tell us about repeated nightly use
300mg is a very high dose not found in most consumer products
The researchers themselves concluded this study does not provide direct evidence CBN is effective for insomnia in routine clinical care
Larger, longer trials using repeated dosing are needed before any conclusions can be drawn about CBN as a sleep treatment
5. Bottom Line
The first clinical trial of CBN for insomnia found it didn't hit its primary goal, but a very high 300mg dose did meaningfully speed up sleep onset — suggesting the science is interesting but significantly behind the marketing.
🗣️ Mary Jane's Take
CBN is everywhere in sleep products right now. This study is a useful reality check — not because CBN is useless, but because most products contain a fraction of the dose that showed any effect, and even that dose didn't pass the main test. Worth knowing before you spend money on a "CBN sleep gummy."
